Skip to content

Eli Lilly and Company broke ground Thursday, Nov. 12, on a $3.5 billion plant in Fogelsville, Pennsylvania, that will make injectable medicines, including the company’s next generation of obesity treatments. In its announcement, the Indianapolis-based drugmaker said the Lilly Lehigh Valley site will create 850 high-wage jobs and approximately 2,000 construction jobs and is expected to be operational by 2031.

The groundbreaking turns a project first announced in January into a construction site. The Pennsylvania governor’s office said in a Nov. 13 release that the plant, at 8810 Main Street in Fogelsville, will be Lilly’s first manufacturing facility in the state, and called the $3.5 billion commitment the largest investment by a life sciences company in Pennsylvania history.

Plant at a glance

ItemWhat was announced
CompanyEli Lilly and Company (NYSE: LLY), headquartered in Indianapolis
Location8810 Main Street, Fogelsville (Upper Macungie Township, Lehigh County), Pennsylvania
Investment$3.5 billion
ProductsInjectable medicines and devices, with a primary focus on next-generation obesity treatments, including investigational retatrutide
Permanent jobs850 high-wage jobs (Lilly); “at least 850” (state)
Construction jobsApproximately 2,000
Expected startOperational by 2031
State support$100 million, including up to $50 million in PA Edge tax credits, a $25 million PA SITES grant and a $25 million Pennsylvania First grant (proposed by the state’s economic development department)
Permit timingState stormwater permit issued in 47 days under the PA Permit Fast Track Program
Green buildingTargeting LEED Gold certification
Plant at a glance: Manufacturers Lists. Investment, jobs, products, timing and LEED target are from Lilly’s Nov. 12, 2026, release; address, state support and permit timing are from the Pennsylvania governor’s office, Nov. 13, 2026.

What the Lilly Lehigh Valley Site Will Make

Lilly said the Fogelsville plant will add capacity for its next generation of obesity medicines, including retatrutide, which the company describes as a first-in-class investigational drug that acts on three hormone receptors: GIP, GLP-1 and glucagon. Retatrutide has not been approved. Lilly says it is studying the drug in several Phase 3 clinical trials and that, as an investigational molecule, it “cannot be legally sold or marketed for human use.”

The site is one of four new Lilly U.S. plants dedicated to injectable medicines and devices. The company’s release lists the other three as Research Triangle Park and Concord, North Carolina, and Kenosha, Wisconsin.

“This $3.5 billion investment means we’ll be able to make these medicines in Pennsylvania for people here at home and around the world.”

Lilly Chair and CEO David A. Ricks, in the company’s Nov. 12 release

At the ceremony, Ricks also said the plant “will be an export site for Lilly,” Pharma Manufacturing reported on Nov. 13. In other words, medicines made in the Lehigh Valley are meant to supply patients overseas as well as in the United States.

Ten New U.S. Sites Since 2020

The Pennsylvania plant is the latest of 10 new U.S. manufacturing sites Lilly has announced since 2020, which the company describes as part of a $50 billion push to expand medicine production in the United States. Lilly’s list breaks down this way:

  • Active pharmaceutical ingredients (five sites): Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two sites in Lebanon, Indiana, including the Lilly Medicine Foundry.
  • Injectable medicines and devices (four sites): Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and the Lehigh Valley.
  • Genetic medicines (one site): Lebanon Advanced Therapies in Lebanon, Indiana.

That mix matters for supply. Five of the 10 sites are meant to make active pharmaceutical ingredients, the core chemical content of a medicine, on U.S. soil, while four, including Fogelsville, are meant to make finished injectable medicines and devices.

The pace has been quick. Lehigh Valley Public Media reported that the Nov. 12 event was Lilly’s third groundbreaking in three weeks, after ceremonies in Houston and Richmond, Virginia.

Automation and Quality Control

Lilly said the plant will use machine learning, AI, digitally integrated systems and advanced data analytics, with automation built in across the site, and that it will “help support a reliable supply of safe, high-quality medicines.”

Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, said in the release that each production run at a Lilly site goes through more than 5,000 documented steps and that each unit is imaged and inspected more than 70 times for defects before a dose leaves the site. Roberto Vázquez Sanabria, site head of Lilly Lehigh Valley, said in a statement quoted by Pharma Manufacturing that “the goal is to have a fully automated process from receiving materials through the warehouse.” Lilly also said the plant is targeting LEED Gold certification for sustainable building performance.

Faster Permits and State Incentives

According to the governor’s office, the state’s Department of Environmental Protection issued Lilly’s stormwater permit in 47 days, which the state said was nearly 60 percent faster than the estimated processing time. The permit moved through the PA Permit Fast Track Program, which was set up by Executive Order 2024-04 to speed reviews for major economic development and infrastructure projects.

The state put its support at $100 million. Per the governor’s office, the Department of Community and Economic Development proposed up to $50 million in tax credits through the PA Edge Tax Credit Program, a $25 million grant through the PA SITES program, and a $25 million Pennsylvania First grant.

Building the Lehigh Valley Workforce

Lilly said it is already hiring in the Lehigh Valley and expects the 850 permanent positions to include engineers, scientists, operations personnel and lab technicians.

To train them, the state committed a Redevelopment Assistance Capital Program award of up to $5 million to a local community college or technical school, and Lehigh Carbon Community College has been selected as one of the recipients, according to the governor’s office. In a February release, the college said it will renovate an existing building into a lab built to mirror Lilly’s manufacturing environment, training lab testers, quality assurance technicians, manufacturing engineers and production specialists.

Lilly also said it will provide up to $1 million over five years to the Upper Macungie Township Community Fund for a new program focused on nutrition, healthy living, fresh food access and health resources for Lehigh Valley families.

Don Cunningham, president and CEO of the Lehigh Valley Economic Development Corp., called it the largest economic development project in Lehigh Valley history in the state’s release, adding that it “ushers in a new era of manufacturing in the Lehigh Valley.”

What to Watch Next

  • Construction and hiring. About 2,000 construction jobs are expected as the site is built and brought online, Lilly said, with the plant expected to be operational by 2031. Wages and hiring dates for the permanent jobs were not published.
  • Retatrutide. The medicine the plant is designed around is still in Phase 3 trials and has not been approved.
  • Job count. Lilly says 850 jobs; the state says “at least 850.”
  • Incentive terms. The $50 million in tax credits is described as “up to” that amount, and the state funding was described as a proposal from the Department of Community and Economic Development.

For another recent drugmaking plant announcement on this site, see the animal health manufacturing plant planned for East Windsor, New Jersey. For a large new U.S. factory in another industry, see the $3 billion auto plant planned for Central Ohio. More drug and medicine makers are listed in the Manufacturers Lists pharmaceutical manufacturers list.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign In